Glu37-Gln325
33 kDa (Reducing)
PBS, pH7.4
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.
Oncogene. 2020 Mar;39(11):2243-2257.
IGFBP-2, or insulin-like growth factor binding protein 2, is a member of the high-affinity binding protein family (IGFBP1-6) and plays a significant role in the regulation of insulin-like growth factors (IGFs) in the central nervous system. This protein is part of a family of six similar proteins that bind to IGF-I and IGF-II, influencing their bioavailability and activity in metabolic signaling. IGFBP-2 can be secreted into the bloodstream, where it binds IGF-I and IGF-II with high affinity, or it can remain intracellular, interacting with various ligands. High expression levels of IGFBP-2 are associated with the growth of several types of tumors and may predict patient recovery chances.
In the biotechnology and pharmaceutical industries, IGFBP-2 is of significant interest due to its implications in various diseases and conditions. The protein's role in tumor growth makes it a potential biomarker and therapeutic target for cancer research. Elevated levels of IGFBP-2 during the progression of many human cancers suggest its importance in oncology.
Additionally, IGFBP-2's involvement in metabolic signaling pathways positions it as a key player in the study and treatment of obesity, diabetes, and other metabolic diseases.
Measured by its ability to inhibit the biological activity of IGF-I MCF‑7 human breast cancer cells. The EC50 for this effect is less than 0.1µg/mL in the presence of rhIGF-I.
2μg (R: reducing condition, N: non-reducing condition).
>95% as determined by SEC-HPLC.
您现在的位置：
